This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis

This study has been completed.
Information provided by (Responsible Party):
Pulmatrix Inc. Identifier:
First received: February 27, 2012
Last updated: July 18, 2013
Last verified: July 2013
The purpose of this study is to determine whether PUR118 is safe and tolerable in a population of subjects with Cystic Fibrosis.

Condition Intervention Phase
Cystic Fibrosis Drug: PUR118 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1 Dose-escalation Study TO Evaluate the Safety and Tolerability of PUR118 and Placebo in Subjects With CF

Resource links provided by NLM:

Further study details as provided by Pulmatrix Inc.:

Primary Outcome Measures:
  • Safety and Tolerability [ Time Frame: 4-6 weeks ]
    Changes in clinical signs and symptoms from physical examination and chest examination, changes in clinical safety laboratory tests, vital signs, spirometry, lung clearance index, 24-hour sputum weight and volume, oxygen saturation, ECG, telemetry, and adverse events.

Secondary Outcome Measures:
  • Pharmacodynamics [ Time Frame: 36 hours ]

    To assess impact of PUR118 on mobilization and expectorated volume of airway mucus secretions.

    To evaluate impact of PUR118 on measurements of lung function, including ventilation inhomogeneity, by both spirometry and measurement of the lung clearance index (LCI).

    To evaluate an impact of PUR118 on sputum, serum and plasma biomarkers related to airway inflammation.

Enrollment: 10
Study Start Date: February 2012
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PUR118 Drug: PUR118
low dose and high dose for 3 doses, BID
Placebo Comparator: Placebo Drug: PUR118
low dose and high dose for 3 doses, BID


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or non-pregnant, non-lactating healthy female.
  • Age 18 to 55 years of age (inclusive) on day of signing informed consent.
  • Subject has a BMI of 17 or greater.
  • Subject has a confirmed diagnosis of cystic fibrosis documented by a compatible clinical or radiographic presentation, and definitive accepted lab and clinical criteria (e.g., sweat chloride > 60 mEq/L or 2 disease causing CFTR mutations) OR is regularly attending a Consultant led clinic where the diagnosis of Cystic Fibrosis is not in doubt.
  • Subject has an FEV1 ≥ 45% of predicted at screening.
  • Subject has an oxygen saturation >92% on room air as determined by pulse oximetry at screening.
  • Subject is a non-smoker or ex-smoker has not smoked for at least six months prior to screening.
  • Subject is otherwise medically stable without clinically significant abnormal screening results that depart from their usual baseline level of health as a subject with CF.
  • Must be willing and able to communicate in English and participate in the whole study.
  • Must provide written informed consent.

Exclusion Criteria:

  • Subject has unstable lung disease, as defined by a change in medical regimen during the preceding 2-weeks, or a significant new finding on chest radiograph (pneumothorax, lobar/segmental collapse), or in the opinion of the Investigator, has had a decline in pulmonary status within the last year not considered a part of the usual, chronic progression of CF lung disease and part of their baseline health condition as a subject with CF.
  • Subject has had an exacerbation of respiratory symptoms within the past 30 days that required initiation of a new or altered respiratory therapy.
  • Subject had either an upper or lower respiratory illness within the 30 days prior to dosing days, or has symptoms from such an illness that have not resolved.
  • Subject has a history of lung transplantation.
  • Females of child bearing potential who are pregnant, or lactating. Females who are sexually active and either not surgically sterile or not willing to use an acceptable form of contraception
  • Clinically significant abnormal biochemistry, haematology or urinalysis not consistent with CF as judged by the Investigator
  • Failure to satisfy the Investigator of fitness to participate for any other reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01543191

United Kingdom
Belfast, Northern Ireland, United Kingdom, BT9 6AD
Sponsors and Collaborators
Pulmatrix Inc.
Principal Investigator: Stephen Smith, MD Celerion
  More Information

Responsible Party: Pulmatrix Inc. Identifier: NCT01543191     History of Changes
Other Study ID Numbers: 601-0009
Study First Received: February 27, 2012
Last Updated: July 18, 2013

Keywords provided by Pulmatrix Inc.:
Lung Diseases
Respiratory Tract Diseases

Additional relevant MeSH terms:
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases processed this record on September 21, 2017